Clinical Trial Update: Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of ACZ885 (canakinumab) in patients with active recurrent or chronic TNF-receptor Associated Periodic Syndrome (TRAP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tnf-receptor Associated Periodic Syndromes

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: TNF-receptor Associated Periodic Syndromes (TRAPS) | Phase 2 | Status: COMPLETED | Results posted: 2016-02-04